Factory 99% Vorinostat Powder CAS 149647-78-9 Chemical Intermediate Vorinostat

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A785
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Vorinostat
• CAS: 149647-78-9
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Vorinostat
Appearance	White Powder
CAS NO.	149647-78-9
Storage	Keep in a cool, dry, dark location

 

Vorinostat is a potent HDAC inhibitor with significant applications in cancer treatment, regulating gene expression, and potentially antiviral activities.

 

1. Anticancer Drug: Vorinostat is primarily utilized as an anticancer agent, particularly in the treatment of cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin's lymphoma that has worsened, persisted, or recurred after two systemic therapies.
2. FDA Approval: It was approved by the U.S. Food and Drug Administration (FDA) in October 2006 for the treatment of skin cancer, marking it as the first FDA-approved drug for metastatic CTCL when other therapies have failed, the disease has worsened, or has returned.
3. Combination Therapy: Vorinostat can also be used in combination with other antitumor drugs to enhance their synergistic effects.

1. HDAC Inhibition: Vorinostat functions by specifically binding to and inhibiting HDAC, including HDAC1, HDAC2, HDAC3 (Class I), and HDAC6 (Class II), thereby altering the acetylation status of histones and other proteins.
2. Gene Expression Regulation: By inhibiting HDAC activity, Vorinostat helps to restore normal gene expression patterns, which are often disrupted in cancer cells. This leads to cell cycle arrest and apoptosis (programmed cell death) in cancer cells.
3. Antiviral Activity: Studies have also shown that Vorinostat has the potential to reactivate latent HIV virus in patients, although further research is needed to fully understand and exploit this antiviral property in clinical settings.